Filtered library · Theme
Oncology & immunology theme · 65 dossiers
Dossiers in the Oncology & immunology theme cluster — 65 names moving on shared catalysts.
All dossiers KYMR Kymera Therapeutics, Inc. fresh LOW Oral STAT6 degrader (KT-621) re-rated on early BROADEN2 enrollment (6/25) and the $10.9B AbbVie–Apogee read-through, but the analyst upgrade cycle topped with RBC's 7/13 downgrade to neutral and the binary topline is 2H-2026 — a maturing,… SYRE Spyre Therapeutics, Inc. fresh LOW Two of three lead binaries (SPY001, SPY002 anti-TL1A) printed potential best-in-class; the stock absorbed a ~$399.7M director-fund block sale and sits back near its ~$102 ATH (~$95). Next legs — SPY003 IL-23 Part A (guided mid-2026,… TNGX Tango Therapeutics, Inc. fresh LOW Post-data digestion, not acceleration: the 92% ORR combo print is fully paid for and the tape has faded from $32.90 to ~$27.7, below the $30.00 June secondary. Sell-side keeps marking up (JPM Overweight $46 on 7/15, Mizuho $40 on 7/17)… RVMD Revolution Medicines, Inc. HIGH Regulatory-clock narrative re-accelerating: the rolling NDA under the FDA National Priority Voucher is "nearing completion" (2026-07-07) and the EMA opened a phased CHMP review the same day, while the Street ceiling walked from ~$186 to… AKTS Aktis Oncology, Inc. MEDIUM The "coverage is spent" read broke: Wedbush ($35) and BMO ($37) initiated Outperform on 2026-08-19, taking the cohort to five, and the 2026-08-13 Q2 reaffirmed Q1 2027 AKY-1189 data with $517.3M cash. Price did not follow — $24.07 on… AUTL Autolus Therapeutics plc fresh MEDIUM Commercial-execution re-rating still working on no new information: after the 2026-08-03 guidance raise to $140–150M and the 2026-08-11 Q2 beat ($45.7M vs $34.0M consensus), the shares printed a new 52-week high at $2.54 and closed $2.41… BMY Bristol-Myers Squibb Co. MEDIUM Legacy-pharma re-rate off the 2026-07-30 guidance reset ($49.0–50.0B sales, $6.75–7.00 adj EPS) is intact, but both attention legs are spent: the AstraZeneca merger was denied 2026-08-05 and the FDA approved ZENBEXUS on 2026-08-13, four… CADL Candel Therapeutics, Inc. MEDIUM Pre-BLA re-rating re-armed: July's round-trip reversed, price reclaimed the June $11.36 high and closed 2026-08-14 at $11.72, 0.7% under the 52-week high, after the 8/13 Q2 print reaffirmed a Q4 2026 prostate BLA and $201.6M cash into Q1… CGEM Cullinan Therapeutics, Inc. MEDIUM CD19 T-cell-engager-in-autoimmune narrative re-rated CGEM ~3x off the $5.68 low on CLN-978 lupus/RA single-dose remissions; now drifting to ~$17.10 in a bull flag under the $19.43 high with the big data catalyst spent and no dated readout… CLDX Celldex Therapeutics, Inc. MEDIUM Single-asset binary: Phase 3 EMBARQ-CSU1/CSU2 topline guided to September/October 2026 at the 2026-08-06 print is the entire equity. The re-rating leg is built — 52-week high $44.87, three Overweight raises 07-29 to 08-07 — and has since… CSTL Castle Biosciences, Inc. MEDIUM Mix-shift repair leg extended without new fundamental content: $29.62 on 2026-08-14 to $34.20 on 2026-08-21, with only an 08-17 Nasdaq Texas dual listing and an 08-20 conference schedule filed in between. TissueCypher +64% YoY still… DCTH Delcath Systems, Inc. MEDIUM Post-print leg held and extended — 2026-08-21 close $17.14, 1.3% under the 52-week high of $17.36 — while the news line went quiet after the 2026-08-11 conference appearance. Nothing company-confirmed is dated until ESMO (2026-10-23) and… DNTH Dianthus Therapeutics, Inc. MEDIUM Complement re-rate has gone quiet: no company disclosure since the 2026-08-04 Q2 print, a fresh 52-week high at $115.96 on a lower RSI than the early-August one, and the next dated binary — MoMeNtum MMN top-line — not until December 2026.… DRTS Alpha Tau Medical Ltd. MEDIUM Head-and-neck re-acceleration: a 2026-06-23 first-ex-US glioblastoma treatment drove a +17.9% breakout to new 52-week highs (~$12.56 on 7/11), reclaiming the $11.99 Tolmar equity shelf. The 2026-07-21 AHNS podium with complete Alpha DaRT +… ELVN Enliven Therapeutics, Inc. MEDIUM Funded single-asset CML story broadening its shareholder base: Barclays initiated Overweight $78, William Blair Outperform and Mizuho raised to $73 all on 2026-08-18, yet the 2026-08-21 close of $59.82 sits 2.1% under the $61.11 high with… GERN Geron Corporation MEDIUM Narrative leg rotated on 2026-08-05/06: RYTELO revenue accelerated to $57.5M (+11% QoQ) and quarterly cash draw shrank to ~$14M from $60M, while management reframed IMpactMF's base case to the H2 2028 final OS analysis — so the… GH Guardant Health, Inc. MEDIUM Q2 (7/30) beat and lifted FY26 to $1.340–1.360B, but the second target wave on 8/3–8/4 (Stephens $195, Piper $193, MS $185) again failed to clear Citi's $215 from 7/8. Fundamentals still stepping up while the sell-side ceiling has been… ICLR ICON plc MEDIUM Restatement discount still unwinding, now with a balance-sheet leg: on 2026-08-06 ICON priced $2.15B of unsecured notes to repay the bridge facility, all secured term loans and the 5.809% 2027 notes, releasing collateral. The 2026-08-21… IDYA IDEAYA Biosciences, Inc. MEDIUM Approval leg intact but between catalysts: the OptimUM-02 win (HR 0.42, ASCO 2026-06-01) feeds a rolling NDA under FDA RTOR guided complete H2 2026, and Q2 (2026-08-04) showed ~$1.24B cash with runway into 2030. Nothing company-dated until… ILMN Illumina, Inc. MEDIUM Post-print give-back fully reversed: $187.96 on 2026-08-07 to a 52-week-high close of $219.40 on 2026-08-21 (+51.9% over three months, RSI 66.3) with no new operating news since the 2026-07-30 beat-and-raise. Price now sits above the… MRNA Moderna, Inc. MEDIUM First-ever positive Phase 3 for an mRNA cancer therapy (INTerpath-001, 2026-08-19) re-rated MRNA 177.0% in one session to $174.38 and swapped the flu-vaccine binary for an oncology-platform story. The narrative is accelerating; the entry… NRIX Nurix Therapeutics, Inc. MEDIUM Roche-partnered BTK degrader moved from validation to execution: first patient in the registrational Phase 3 DAYBreak CLL-306 on 2026-08-04, RBC to $36 on 2026-08-10, price to a new 52-week high on 2026-08-14. Narrative still accelerating,… NVCR NovoCure Limited MEDIUM Post-TRIDENT commercial-inflection leg intact but undated: the 2026-07-23 Q2 print (rev $183.584M vs $172.437M cons., first positive adj. EBITDA $10.8M, FY guide to $710–725M) still sets the frame, and on 2026-08-22 Zacks flagged upward… ONC BeOne Medicines Ltd. MEDIUM Q2 print resolved bullish — revenue $1.705B vs $1.591B est., non-GAAP EPS/ADS $3.84 vs $1.44, FY26 guide raised to $6.6–6.8B — but the stock is still 7.9% under the $377.47 52-week high and the 2026-08-06 target wave was increments, not… ORKA Oruka Therapeutics, Inc. MEDIUM Supply overhang cleared: the 2026-07-01 Fairmount $300M block at $84.43 was absorbed and price closed $92.70 on 07-17 (+11.6%), 5% off the 52-week high, with 19.85% short interest still rising. Long-acting I&I re-rated by the $10.9B… PGEN Precigen, Inc. MEDIUM PAPZIMEOS launch-ramp durability is the binary — the first FDA-approved RRP therapy printed $21.6M net product revenue in Q1 2026, and the now-confirmed Aug 4 Q2 print (announced Jul 21) grades whether the ramp compounds sequentially or… RLAY Relay Therapeutics, Inc. MEDIUM Coverage-driven leg intact but thinning: HC Wainwright's $29 raise (2026-08-20) was the fourth in 14 days and the first that failed to make a new high, with the 2026-08-21 close at $19.44 versus a $20.75 52-week high. No dated company… SNDX Syndax Pharmaceuticals, Inc. MEDIUM Menin-inhibitor commercial ramp accelerating: Revuforj + Niktimvo franchise cleared $100M/quarter with revenue +224% YoY, and the leg being bought is frontline AML label expansion (~10x TAM). Stock coils below 52-week-high resistance… URGN UroGen Pharma Ltd. MEDIUM The 2026-08-05 binary resolved upward: ZUSDURI Q2 net revenue $50.4M (+73% QoQ off the $29.2M Q1 base), total revenue $72.456M vs $63.526M consensus, and a ~22% one-day gap to a $49.00 52-week high. The ramp now runs into an empty calendar… VCYT Veracyte, Inc. MEDIUM Sell-side is now chasing a move it missed: VCYT broke to a 52-wk high $60.91 (closed $59.13 on 2026-07-17, +124% YoY) as Piper initiated Overweight $66 (07-15) and Canaccord lifted a Hold PT $42→$60. Fundamentals still accelerating (Q1 rev… VSTM Verastem, Inc. MEDIUM Post-Q2 the narrative is confirmed and the tape has flattened: $6.74 on 2026-08-07 to $6.89 on 2026-08-21 while three banks cut targets with ratings held. The 2026-08-28 Oberland closing funds $50M inside 30 days; the October VS-7375… XNCR Xencor, Inc. MEDIUM Two overhangs closed in three weeks: the $105M Alexion settlement (2026-07-29) ended the Ultomiris dispute and pushed runway through 2028, and Q2 revenue of $51.2M vs $18.9M consensus (2026-08-05) drew three price-target raises on 08-06.… ZBIO Zenas BioPharma, Inc. MEDIUM First-in-disease B-cell modulator: obexelimab BLA (IgG4-RD, 56% flare cut, HR 0.44) hit the FDA 2026-05-28, and the ~60-day filing determination — acceptance plus a possible Priority Review grant — is due within days, a fresh near-term… ZURA Zura Bio Limited MEDIUM Q2 print (2026-08-11) added a third tibulizumab indication — polymyalgia rheumatica, NEXUS-PMR Phase 2 by YE2026 — and Wedbush ($22) plus Guggenheim ($20) raised targets on 2026-08-12; the $5.57 close on 2026-08-14 has not paid for it. The… ALMS Alumis Inc. LOW Psoriasis leg is fully told — 2026-08-10 ONWARD3 48-week data (75% PASI 90 / 54% PASI 100) left the stock 16.5% under its $30.30 52-week high. The only re-rating leg left is the undated LUMUS Phase 2b lupus topline, reaffirmed for Q3 2026… ANAB AnaptysBio, Inc. LOW The dateless wait acquired a docket: a 2026-07-28 stipulation set post-trial briefing to an Oct 20 Chancery argument, and ANAB has rebuilt from ~$54 (Jul 24) to $58.47 (Aug 14) on no company news. The written opinion deciding Jemperli… APGE Apogee Therapeutics, Inc. LOW HSR expiry (2026-08-05) and shareholder approval (2026-08-11) cleared the last stated conditions on AbbVie's $135.11 all-cash takeout, so what trades now is terminal merger-arb carry into a company-guided Q3-2026 close — capped at the bid,… ARCT Arcturus Therapeutics Holdings Inc. LOW CSL exit hands back global KOSTAIVE plus flu/RSV/EBV rights, $12M cash and ~$16M of released liabilities, against $191.5M cash and runway guided through end-2028 — a platform-repossession re-rating that has run 91.3% in three months into… AVXL Anavex Life Sciences Corp. LOW Governance, not approval, is the leg: PVG's six-nominee GOLD slate meets the board's WHITE slate at the 2026-09-24 annual meeting. Since 2026-08-15 the contest kept filing (8-K 08-17, DFAN14A 08-19) while price stalled — $3.24 on… BCAX Bicara Therapeutics Inc. LOW Bifunctional EGFR/TGF-β narrative in HPV-negative head & neck cancer stalled after the ASCO 2026 three-year-OS re-rate: $27.76 close is ~10% off the $30.99 high on roughly half prior turnover, consensus PT ~$31.46 sits only 13% above spot,… BIOA BioAge Labs, Inc. LOW The ESC venue hypothesis failed: ZEUS is absent from the published ESC 2026 Hot Line programme (Munich, 2026-08-28 to 08-31), so the full dataset that would separate NLRP3 from IL-6 blockade does not land in August and no substitute date… BOLD Boundless Bio, Inc. LOW Merger-arb wrapper, not an oncology stock: the object is a planned $44–48M pre-close cash dividend plus a 3.69% stub in the AATD base-editing NewCo. Week of 2026-08-14 added owners (ADAR1 13G at 8.8%) but no deal documents — still no S-4,… CORT Corcept Therapeutics Incorporated LOW Lifyorli oncology launch (approved 2026-03-25, NCCN preferred) re-accelerated the tape to fresh 52-week highs near $92, and the 2026-06-17 Cushing's relacorilant resubmission (~Dec PDUFA) adds second-approval optionality. But a fresh entry… CRVS Corvus Pharmaceuticals, Inc. LOW Calendar still empty until 2027 after the 2026-08-06 push-out (PTCL futility Q1 2027, no data released; SIERRA1 topline Q3 2027), but the tape has recovered: $14.46 close on 2026-08-21 with RSI 62.4 versus $13.92 and RSI 47.5 on… ERAS Erasca, Inc. LOW Funded pan-RAS story with part of its calendar restored: the 2026-08-11 Q2 release dates ERAS-4001 BOREALIS-1 preliminary Phase 1 data to H2 2026, ahead of the H1 2027 ERAS-0015 cut. But the 2026-08-21 close of $17.63 sits on the $17.50… EVH Evolent Health, Inc LOW The late-June retail bounce has fully unwound — EVH traded ~$5.76 on 2026-07-07, back under the $6.59–6.86 consensus target band and well under Truist's flat $7. Nothing carries the name now except the confirmed 2026-08-06 Q2 print, which… FTRE Fortrea Holdings Inc. LOW Post-spin margin-repair narrative is now fully written into sell-side models and no longer into the tape: five target raises through 2026-08-04 (TD Cowen $23) met a slide from $19.17 (7/31) to $17.41 (8/14), surrendering the July… GLUE Monte Rosa Therapeutics, Inc. LOW ZEUS (ziltivekimab, MACE HR 0.99) failed on 2026-07-31 and took GLUE −27.16% to $16.52, its worst session on record, because the hsCRP-to-outcomes link under MRT-8102's ASCVD story is exactly what ZEUS could not demonstrate. Platform,… IMMX Immix Biopharma, Inc. fresh LOW Single-asset CAR-T regulatory story: NXC-201 posted a 95% CR rate (19/20) in NEXICART-2 on 2026-05-21 and holds FDA Breakthrough Therapy Designation from 2026-01-28, with a BLA guided for 2026. Price closed 2026-08-21 at its 52-week high… IMRX Immuneering Corporation LOW Busted-catalyst pancreatic biotech: atebimetinib's 17.3-mo single-arm 1L OS is real, but the Phase 3 binary is mid-2028 and the tape keeps fading post-ASCO ($5.11→$4.32 in two weeks) even as targets climb to $18–$30. Cheap… INBX Inhibrx Biosciences, Inc. LOW Non-dilutive bridge into the 2027-04-14 PDUFA, with one item pulled forward: the 2026-08-13 Q2 release moved the INBRX-106 HNSCC PFS readout into Q3 2026 and dated the CRC registrational FDA meeting to Q4 2026. But the two-week advance… JBIO Jade Biosciences, Inc. LOW The post-Q2 revision leg round-tripped: $24.71 on 2026-08-14 back to $21.34 on 2026-08-21, with the 2026-08-11 target raises (Wedbush $47, Jefferies $48 from $40) marking the high rather than starting a leg. The July shelf near $21 is now… KURA Kura Oncology, Inc. LOW The binary already fired: KOMZIFTI's 2025-11-13 approval and ~40% R/R NPM1 share are priced, and the $24–28 targets need a frontline Phase 3 that doesn't read until 2028. The tape is drifting — $10.39, lower third of the H1 range. A… LEGN Legend Biotech Corporation LOW In-vivo CAR-T re-rate has matured into digestion: EHA (6/13) confirmed LB2501's 100% ORR and clean durability, but the 6/17 $226M raise at $29.35 capped the leg and JPM's 7/13 Neutral $35 reinstatement caps the Street. No fresh catalyst… MEDP Medpace Holdings, Inc. LOW Bookings-inflection leg (Q2 awards $795.7M, +28.2% YoY, book-to-bill 1.13x, FY26 guides raised 2026-07-22) is intact on fundamentals but stalled on the tape: the $620.59 high faded to a $578.5 close on 2026-08-14, RSI 45, while the CEO… NUVL Nuvalent, Inc. LOW Closed, not pending: GSK completed the $124 all-cash acquisition on 2026-07-15 after 91.3% of shares were tendered by the 2026-07-14 expiry; trading was suspended 2026-07-15 and Form 25 delisting requested. No US-listed NUVL equity remains… ORIC Oric Pharmaceuticals, Inc. LOW mCRPC PRC2 story de-risked as rinzimetostat enters registrational Phase 3 (Himalayas-1, 2026-07-14) with Bayer supplying NUBEQA and a J&J-backed enozertinib lung program behind it. But pivotal data is 2028+, so the only near-term mover is… RLMD Relmada Therapeutics, Inc. LOW The level this coverage was framed around broke: the 2026-08-21 weekly close of $4.63 is under the $4.75 March PIPE strike, and it broke on no disclosure. With the 2026 clinical calendar emptied on the 2026-08-06 call, what remains is a… RLYB Rallybio Corporation LOW No new filing since the 2026-08-06 10-Q: as of 2026-08-23 the 2026-07-15 S-4 is still not effective, with no record date or meeting date set. The 2026-08-21 close of $16.83 sits ~7% above the ~$15.68/share implied by the S-4's $83.2M Net… RZLT Rezolute, Inc. LOW A 10.7% week to $5.09 on 2026-08-21 with zero company news since the 2026-07-21 conference notice — the bid arrived via Friday-gainer screens, not a disclosure. The 2026-06-02 upLIFT interim (6 of 8 responders) is still the entire story,… SLS SELLAS Life Sciences Group, Inc. LOW Cancer-vaccine sector re-rate after Merck/Moderna's 2026-08-19 Phase 3 win carried SLS to a 52-week closing high of $15.46 on 2026-08-21 (+15.4% on the session, RSI 78.7) with no SELLAS data of its own; REGAL's last published count is… STRO Sutro Biopharma, Inc. LOW Single-asset binary now inside its own catalyst window: the STRO-004 (DAR8 Tissue Factor exatecan ADC) Phase 1 readout was guided "mid-2026" and that window is expiring undated. Price has gone flat at ~$29.7 for four weeks after the June… TGTX TG Therapeutics, Inc. LOW The catalyst leg is spent; what is left is whether the $46–48 shelf holds through a two-month news vacuum into year-end subcutaneous Phase 3 topline. VIR Vir Biotechnology, Inc. LOW Q2 (2026-08-05) printed $238.9M revenue and $0.47 diluted EPS on Astellas upfront recognition — an accounting swing, and the tape read it as one: $9.24 on 2026-08-14, still under the $10.36 Astellas equity strike, with Morgan Stanley and… VOR Vor Biopharma Inc. LOW Legacy-pivot re-rating held its breakout through the 2026-08-11 Q2 miss — $23.36 close on 2026-08-21 against $23.67 on 08-07 — but the same release disclosed $48.4M of ATM stock sold into July strength. With UPSTREAM MG topline guided…